AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Trials to obtain full regulatory approval as a biological for its ultra shortcourse immunotherapy, Pollinex Quattro, have progressed well in the EU, and are back on-track in the US with a planned new safety trial. Meanwhile, AGY acquired novel virus-like particle (VLP) technology with the goal to develop a short-course therapeutic vaccine for peanut allergy. Positive safety and efficacy results from proof-of-concept pre-clinical tests with Polyvac Peanut are very encouraging. A small safety study in humans is required before Phase I trials can commence.